Plus Therapeutics (PSTV) Retained Earnings (2010 - 2026)
Plus Therapeutics (PSTV) reported Retained Earnings of -$522.8 million for Q1 2026, down 2.34% year-over-year from -$535.3 million in Q1 2025, and down 1.35% quarter-over-quarter from -$515.9 million in Q4 2025.
Plus Therapeutics (PSTV) Retained Earnings (2010 - 2026) Analysis & Trends
Plus Therapeutics (PSTV) has 17 years of Retained Earnings data on file, last reported at -$522.8 million in Q1 2026.
- Retained Earnings for Q1 2026 came in at -$522.8 million, down 2.34% year-over-year; the trailing twelve-month figure through Mar 2026 was -$522.8 million (down 2.34% YoY), and the FY2025 annual result was -$515.9 million, down 4.54% from the prior year.
- Retained Earnings fell to -$522.8 million in Q1 2026 per PSTV's latest filing, from -$515.9 million in the prior quarter.
- Over five years, Retained Earnings peaked at -$451.0 million in Q1 2022 and troughed at -$522.8 million in Q1 2026.
- A 5-year average of -$485.7 million and a median of -$483.8 million in 2024 frame the typical range for Retained Earnings.
- The sharpest annual moves came in 2025 and 2026: Retained Earnings fell 5.6% in 2025, then declined 2.34% in 2026.
- A 5-year view of Retained Earnings shows it stood at -$467.2 million in 2022, then decreased by 2.85% to -$480.5 million in 2023, then declined by 2.7% to -$493.5 million in 2024, then fell by 4.54% to -$515.9 million in 2025, then slipped by 1.35% to -$522.8 million in 2026.
- Business Quant data shows PSTV's Retained Earnings at -$522.8 million in Q1 2026, -$515.9 million in Q4 2025, and -$510.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | -153.89 Mn |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | -211.85 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 1.00 Bn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | -279.00 Mn |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | 130.89 Mn |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | -1.88 |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 14.59 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | -838.07 Mn |
| 10 | Plus Therapeutics | 34.26 Mn | 19.15 Mn | - | -522.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -522.81 Mn |
| Dec 31, 2025 | -515.87 Mn |
| Sep 30, 2025 | -510.15 Mn |
| Jun 30, 2025 | -505.73 Mn |
| Mar 31, 2025 | -510.88 Mn |
| Dec 31, 2024 | -493.48 Mn |
| Sep 30, 2024 | -489.58 Mn |
| Jun 30, 2024 | -486.70 Mn |
| Mar 31, 2024 | -483.80 Mn |
| Dec 31, 2023 | -480.50 Mn |
| Sep 30, 2023 | -476.69 Mn |
| Jun 30, 2023 | -473.50 Mn |
| Mar 31, 2023 | -472.00 Mn |
| Dec 31, 2022 | -467.19 Mn |
| Sep 30, 2022 | -461.50 Mn |
| Jun 30, 2022 | -456.30 Mn |
| Mar 31, 2022 | -451.03 Mn |
| Dec 31, 2021 | -446.91 Mn |
| Sep 30, 2021 | -442.76 Mn |
| Jun 30, 2021 | -439.03 Mn |